Vaginal microbicides: What does the future hold?

Article

New antimicrobial agents that hold promise against HIV and other sexually transmitted diseases are now being tested. Agents include Acidform, BufferGel and dapivirine.

Key Points

Our goal here is to review the various microbicides currently being tested, outlining their mechanism of action, potential usefulness, and safety profile.

A spermicide with little or no microbicidal properties

Unfortunately research proved the agent less than ideal.3 Beginning in 1990, randomized controlled trials compared different N-9 formulations-sponge, film, and various gels-and dosages3-7 for their efficacy against HIV and other STDs. Taken together, these studies showed little if any protection against HIV, gonorrhea, and chlamydia. In one trial, women who used N-9 gel actually had higher rates of HIV than women using placebo gel.8

How do microbicides work?





Another polyanion gel-Pro2000/5-is currently being evaluated in large-scale effectiveness trials, which should have evidence within a year. The higher dose arm (2%) of Pro2000/5 was halted in February because the data could not show it was effective. The lower dose (0.5%) is continuing to be evaluated in two separate trials. Pro2000/5 may also have contraceptive activity. Another potential group of contraceptives, dendrimers, such as VivaGel, are highly branched macromolecules that also prevent HIV from attaching to the target cells.10 VivaGel is currently in safety studies.

While polyanions are nonspecific in the way they work, several HIV-specific entry/fusion inhibitors are also in development as microbicides, including drugs that block gp-41 fusions and CCR5-receptor binding.

Recent Videos
HPV self-collection: Benefits, limitations, and future implications | Image Credit: forhers.com
Improving pediatric HPV vaccination rates: Early initiation and addressing disparities | Image Credit: blog.nemours.org.
New cervical cancer screening guidelines: What practitioners needs to know | Image Credit: forhers.com
COVID-19 Therapy Roundtable: Focusing on inpatient care
COVID-19 Therapy Roundtable: Defining the virus today and treatment options
How fezolinetant advances non-hormonal treatment of hot flashes | Image Credit: medschool.cuanschutz.edu
Contraceptive access challenges for college students in contraception deserts | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.